Neurocrine Biosciences (NBIX) Change in Accured Expenses (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Change in Accured Expenses of -$8.5 million for Q2 2026, down 156.29% year-over-year from $15.1 million in Q2 2025, and up 40.56% on a QoQ basis from -$14.3 million in Q1 2026.
Neurocrine Biosciences (NBIX) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Change in Accured Expenses for 17 years, with the latest figure at -$8.5 million in Q2 2026.
- Change in Accured Expenses for Q2 2026 came in at -$8.5 million, down 156.29% year-over-year; the trailing twelve-month figure through Jun 2026 was $125.3 million (down 6.21% YoY), and the FY2025 annual result was $160.2 million, up 269.12% from the prior year.
- Change in Accured Expenses grew to -$8.5 million in Q2 2026, from -$14.3 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $124.4 million in Q3 2023 and troughed at -$98.3 million in Q4 2023.
- A 5-year average of $19.1 million and a median of $15.6 million in 2023 frame the typical range for Change in Accured Expenses.
- The widest annual swing landed in 2023, when Change in Accured Expenses surged 279.27%; it then tumbled 467.28% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at $37.6 million in 2022, then plunged by 361.44% to -$98.3 million in 2023, then jumped by 178.64% to $77.3 million in 2024, then retreated by 1.03% to $76.5 million in 2025, then tumbled by 111.11% to -$8.5 million in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were -$8.5 million in Q2 2026, -$14.3 million in Q1 2026, and $76.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn | 41.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.50 Mn |
| Jun 30, 2026 | -8.50 Mn |
| Mar 31, 2026 | -14.30 Mn |
| Mar 31, 2026 | -14.30 Mn |
| Dec 31, 2025 | 76.50 Mn |
| Dec 31, 2025 | 76.50 Mn |
| Sep 30, 2025 | 55.80 Mn |
| Sep 30, 2025 | 55.80 Mn |
| Jun 30, 2025 | 30.90 Mn |
| Jun 30, 2025 | 30.90 Mn |
| Mar 31, 2025 | -3.00 Mn |
| Mar 31, 2025 | -3.00 Mn |
| Dec 31, 2024 | 77.30 Mn |
| Dec 31, 2024 | 77.30 Mn |
| Sep 30, 2024 | 44.20 Mn |
| Sep 30, 2024 | 44.20 Mn |
| Jun 30, 2024 | -59.50 Mn |
| Jun 30, 2024 | -59.50 Mn |
| Mar 31, 2024 | -18.60 Mn |
| Mar 31, 2024 | -18.60 Mn |